sur ADOCIA (EPA:ADOC)
Adocia Progresse with AdoXLongTM and BioChaperone®
Adocia, a Lyon-based biopharmaceutical company, has announced the filing of a patent for its new AdoXLong™ platform, which prolongs the action of peptides for the treatment of diabetes and obesity. This innovation would allow patients to switch from weekly to monthly injections, thus improving therapeutic persistence.
The patent initially covers semaglutide, with promising results indicating potential efficacy for a monthly injection. The technology is compatible with a variety of metabolic peptides such as GLP-1 and GIP.
In parallel, Adocia is continuing the development of its BioChaperone® platform with two feasibility studies with anonymous pharmaceutical companies. This platform aims to stabilize and combine hormones to treat diabetes and obesity, thus strengthening its therapeutic offering.
R. P.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de ADOCIA